PROOFWAKE BIO

WORKED EXAMPLE · PUBLIC RECORDS

UBX1325 for diabetic macular edema

The company reported better news at some time points. The trial still missed the main test it was set up to answer.

Stop: no more spend on this screen

Public sources checked November 21, 2026. This is a decision about what to check next for a business lead, not medical, legal or investment advice.

1. What happened in people?

Trial record and sponsor-reported result

In the randomized ASPIRE trial, Unity compared UBX1325 with aflibercept in people with diabetic macular edema. The company’s results filing says it did not show that the vision outcome was close enough to aflibercept on the main measure, the average of weeks 20 and 24. A result at week 36 did meet the study’s comparison criterion; it did not change the primary result.

2. Why did the work stop?

Documented in company filings

Unity said it was closing out ASPIRE while cutting costs and weighing its options. Its proxy filing describes the business decision. The dissolution filing gives an effective date of September 26, 2025.

3. Who might control the rights or data?

Not known

Unity was the study sponsor. Its dissolution does not tell us who can license the drug or release the full trial data today. We did not verify a current rights holder or data custodian.

4. What is the next useful question?

Proofwake’s first-screen judgment

Do not spend on this lead now. If it comes back, ask for a verified rights and data contact and new evidence that directly addresses the missed main result. This is not a claim that the drug can never be useful.

Ask about a brief for your lead Compare all three examples